Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05040698 |
Recruitment Status :
Completed
First Posted : September 10, 2021
Last Update Posted : March 1, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hidradenitis Suppurativa | Drug: Fostamatinib | Phase 2 |
Sample size: 20 patients Study duration: 16 weeks
Primary Endpoints:
Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 4 compared to Baseline.
Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 12 compared to Baseline.
Secondary Endpoints:
Safety and Tolerability (Grade 2/3 Adverse Effects); Changes in Disease Activity (Measures by AN count and IHS4 scoring).
Study procedures Clinical Examination, Patient Questionnaires, Skin Biopsy, Blood Draw, medical photography
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Exploratory, Proof-of-Concept Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa |
Actual Study Start Date : | October 1, 2021 |
Actual Primary Completion Date : | January 13, 2023 |
Actual Study Completion Date : | January 27, 2023 |
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Arm | Intervention/treatment |
---|---|
Experimental: Open Label Fostamatinib
Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
|
Drug: Fostamatinib
Open label Fostamatinib
Other Names:
|
- Week 4 evaluation [ Time Frame: 4 weeks ]Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 4 compared to
- Week 12 evaluation [ Time Frame: 12 weeks ]Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 12 compared to Baseline
- Grade 2/3 Adverse Events [ Time Frame: 12 weeks ]Number of Grade 2/3 Adverse Effects of Fostamatinib over the 12 Week course of treatment.
- Abscess and Nodule Count Week 4 [ Time Frame: 4 weeks ]Changes in Abscess and Nodule count at Week 4 compared to baseline
- International Hidradenitis Suppurativa Severity Score (IHS4) Week 4 [ Time Frame: 4 weeks ]Changes in IHS4 score at Week 4 compared to baseline
- Abscess and Nodule count week 12 [ Time Frame: 12 weeks ]Changes in Abscess and Nodule count at Week 12 compared to baseline
- International Hidradenitis Suppurativa Severity Score (IHS4) Week 12 [ Time Frame: 12 weeks ]Changes in IHS4 score at Week 12 compared to baseline
- Physician Rated Overall Disease Severity [ Time Frame: 12 weeks ]Changes in physician rated overall disease severity by visual analogue scale (0-10) at week 12 compared to baseline
- Dermatology Life Quality Index (DLQI) [ Time Frame: 12 weeks ]Changes in the DLQI (0-30) at week 12 compared to baseline
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Moderate to Severe (Hurley Stage 2 or 3) Hidradenitis Suppurativa as determined by the PI
Exclusion Criteria:
- Uncontrolled hypertension (systolic blood pressure [BP] ≥135 mmHg and/or diastolic BP ≥85 mmHg), unstable angina, congestive heart failure of New York Heart Association classification III or IV, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia) at screening.
- History of myocardial infarction within 3 months prior to screening.
- Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine at screening or at randomization.
- Renal function impairment with creatinine clearance <30 mL/min at screening (estimated glomerular filtration rate will be calculated using the modification of diet in renal disease equation).
- Liver function impairment with aspartate aminotransferase/alanine aminotransferase >=3x the upper limit of normal or bilirubin >2X the upper limit of normal at screening.
- Neutrophil count <1000/µL at screening.
- History of an allergic reaction or hypersensitivity to the study treatment or any component of the study treatment formulation.
- Has documented HIV infection or documented, active hepatitis B or hepatitis C infection.
- Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half-lives of the drug, whichever is longer).
- Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05040698
Australia, New South Wales | |
Holdsworth House Medical Practice | |
Sydney, New South Wales, Australia, 2010 |
Principal Investigator: | John Frew, MBBS | Holdsworth House Medical Practice |
Responsible Party: | John Frew, Principal Investigator, Holdsworth House Medical Practice |
ClinicalTrials.gov Identifier: | NCT05040698 |
Other Study ID Numbers: |
JFR-001 |
First Posted: | September 10, 2021 Key Record Dates |
Last Update Posted: | March 1, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
fostamatinib HS Tavalisse |
Hidradenitis Suppurativa Hidradenitis Inflammation Pathologic Processes Sweat Gland Diseases Skin Diseases |
Skin Diseases, Bacterial Bacterial Infections Bacterial Infections and Mycoses Infections Skin Diseases, Infectious Suppuration |